



The Emirates Anticancer Pharmaceuticals is pleased to announce that on 29<sup>th</sup> September 2011 joined the project consortium Nanobot Research Group (NRG) as a participant of the application project's outputs of basic research and development activities, planned in 2012 - 2015. Company Emirates Anticancer Pharmaceuticals expects from the participation in the project consortium availability of suitable nano-carriers for anticancer agents from its own development.

Raffat El Sayed  
Emirates anticancer Pharmaceuticals  
(CEO)

